Safety and Efficacy of Tirofiban Combined With Mechanical Thrombectomy Depend on Ischemic Stroke Etiology
| العنوان: | Safety and Efficacy of Tirofiban Combined With Mechanical Thrombectomy Depend on Ischemic Stroke Etiology |
|---|---|
| المؤلفون: | Chaoping Huang, Yajie Shan, Linda Nyame, Bai-Li Song, Yang Zou, Chao Sun, Fusang Wang, Xiaohan Zheng, Xuemei Li, Xiang Li, Jianjun Zou, Junshan Zhou, Mako Ibrahim, Yukai Liu, Zheng Zhao, Xiangliang Chen, Zhihong Zhao, Jue Hu |
| المصدر: | Frontiers in Neurology Frontiers in Neurology, Vol 10 (2019) |
| بيانات النشر: | Frontiers Media SA, 2019. |
| سنة النشر: | 2019 |
| مصطلحات موضوعية: | safety, acute ischemic stroke, tirofiban, medicine.medical_specialty, Multivariate analysis, efficacy, 030204 cardiovascular system & hematology, lcsh:RC346-429, mechanical thrombectomy, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, medicine, Stroke, Acute ischemic stroke, lcsh:Neurology. Diseases of the nervous system, Original Research, Intracerebral hemorrhage, business.industry, Tirofiban, medicine.disease, Mechanical thrombectomy, Neurology, Ischemic stroke, Etiology, Neurology (clinical), business, 030217 neurology & neurosurgery, medicine.drug |
| الوصف: | Background and Purpose: The clinical use of tirofiban for patients with acute ischemic stroke (AIS) who underwent mechanical thrombectomy (MT) remains controversial. We aimed to evaluate the safety and efficacy of tirofiban combined with MT in AIS patients. Methods: Patients with AIS who underwent MT from January 2014 to December 2018 were enrolled in three stroke units in China. Subgroup analyses were performed based on stroke etiology which was classified according to the Trial of ORG 10172 in Acute Stroke Treatment (TOAST) criteria. Safety outcomes were in-hospital intracerebral hemorrhage (ICH), symptomatic intracerebral hemorrhage (sICH) and mortality at 3-month. Efficacy outcomes were favorable functional outcome and functional independence at 3-month and neurological improvement at 24 h, 3 d and discharge. Results: In patients with large artery atherosclerosis (LAA) stroke, multivariate analyses revealed that tirofiban significantly decreased the odds of in-hospital ICH (adjusted OR = 0.382, 95% CI 0.180–0.809) and tended to increase the odds of favorable functional outcome at 3-month (adjusted OR = 3.050, 95% CI 0.969–9.598). By contrast, in patients with cardioembolism (CE) stroke, tirofiban was not associated with higher odds of favorable functional outcome at 3-month (adjusted OR = 0.719, 95% CI 0.107–4.807), but significantly decreased the odds of neurological improvement at 24 h and 3d (adjusted OR = 0.185, 95% CI 0.047–0.726; adjusted OR = 0.268, 95% CI 0.087–0.825). Conclusions: Tirofiban combined with MT appears to be safe and effective in LAA patients, but has no beneficial effect on CE patients. |
| تدمد: | 1664-2295 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8be5ac2be2899d3858f3fa4e4040f7a3 https://doi.org/10.3389/fneur.2019.01100 |
| حقوق: | OPEN |
| رقم الأكسشن: | edsair.doi.dedup.....8be5ac2be2899d3858f3fa4e4040f7a3 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 16642295 |
|---|